Information Provided By:
Fly News Breaks for March 3, 2020
INO
Mar 3, 2020 | 11:56 EDT
Inovio Pharmaceuticals this morning announced an accelerated timeline for development of its COVID-2019 vaccine candidate INO-4800. The company anticipates having 3,000 doses manufactured for clinical studies in March and expects to start dosing healthy volunteers in the U.S. in April followed by study starts in China and South Korea, Cantor Fitzgerald analyst Charles Duncan tells investors in a research note. Inovio expects to have data in fall 2020. Duncan views this timeline as "feasible in light of the company's experience developing vaccines in an expeditious manner." Inovio's broad platform experience, including ongoing Phase 3 studies of VGX-3100 in cervical dysplasia, reduces its execution risk, contends the analyst in a note titled "DNA-Based Platform Gaining Traction in COVID-19 Therapeutics Race." Ducan keeps an Overweight rating on Inovio with a $12 price target. The stock in midday trading is up 16% to $5.10.
News For INO From the Last 2 Days
There are no results for your query INO